As filed with the Securities and Exchange Commission on February 2, 2009

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE TO

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

AMENDMENT NO. 1

THRESHOLD PHARMACEUTICALS, INC.

(Name of Subject Company (Issuer) and Filing Persons (Offeror))

Certain Options to Purchase Common Stock under the Threshold Pharmaceuticals, Inc.

2004 Amended and Restated Equity Incentive Plan

(Title of Class of Securities)

885807107

(CUSIP Number of Class of Securities) (Underlying Common Stock)

Harold E. Selick, Ph.D.

Chief Executive Officer

Threshold Pharmaceuticals, Inc.

1300 Seaport Boulevard, Suite 500

Redwood City, California 94063

(650) 474-8200

(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing person.)

Copies to:

Stephen B. Thau

Morrison & Foerster LLP

755 Page Mill Road

Palo Alto, California 94304

Telephone: (650) 813-5640

Facsimile: (650) 251-3745

Calculation of Filing Fee

Check the appropriate boxes below to designate any transactions to which the statement relates:

Check the following box if the filing is a final amendment reporting the results of the tender offer:  ¨

This Amendment No. 1 amends and supplements the Tender Offer Statement on Schedule TO (as amended, this “Schedule TO”) filed by Threshold Pharmaceuticals, Inc., a Delaware corporation (“Threshold” or the “Company”), with the Securities and Exchange Commission on January 12, 2009. This Schedule TO relates to an offer (the “Offer”) by Threshold pursuant to which eligible employees, consultants, executive officers and directors have the opportunity to make a one-time election to cancel certain outstanding grants of stock options (the “Current Options”) under the Threshold Pharmaceuticals, Inc. 2004 Amended and Restated Equity Incentive Plan (the “Plan”) for an equal number of new unvested options to be granted under the Plan after the date of cancellation of the Current Options (the “Replacement Options”). The Replacement Options are subject to terms and conditions set forth in this amended Schedule TO and the exhibits hereto.

The safe harbor protections for forward-looking statements contained in the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, do not apply to any forward-looking statements made in connection with this Offer.

The information set forth under “Summary Term Sheet” in the Amended Option Exchange Program Tender Offer Statement dated February 2, 2009 (the “Offer to Exchange”), attached hereto as Exhibit (a)(2), is incorporated herein by reference.

(a) The name of the issuer is Threshold Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the address of its principal executive offices is 1300 Seaport Boulevard, Suite 500, Redwood City, California 94063, and its telephone number is (650) 474-8200.

(b) This Tender Offer Statement on Schedule TO relates to an offer by the Company to Eligible Persons, as defined in the Offer to Exchange, to exchange certain options to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), granted between February 10, 2005 and December 31, 2008 that are currently outstanding (the “Eligible Options”) under the Threshold Pharmaceuticals, Inc. 2004 Amended and Restated Equity Incentive Plan (the “Plan”).

In exchange for the Eligible Options, tendering option holders will receive Replacement Options to purchase shares of Common Stock. The Replacement Options will be issued under the Plan, upon the terms and subject to the conditions described in the Offer to Exchange and the related Form of Letter of Transmittal attached hereto as Exhibit (a)(4) (the “Letter of Transmittal,” and together with the Offer to Exchange, as they may be amended or supplemented from time to time, the “Offer”). As of January 12, 2009, Eligible Options to purchase 569,548 shares of Common Stock were outstanding under the Plan.

The information set forth in the Offer to Exchange under Section 1 “Eligible Persons,” Section 2 “Number of Options; Expiration Date,” Section 6 “Acceptance of Options for Exchange and Issuance of Replacement Options” and Section 8 “Source and Amount of Consideration; Terms of Replacement Options” is incorporated herein by reference.

(c) The information set forth in the Offer to Exchange under Section 7 “Price Range of Common Stock Underlying the Options” is incorporated herein by reference.

The Company is the filing person. The information set forth under Item 2(a) above is incorporated herein by reference. The information set forth in the Offer to Exchange under Section 10 “Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Current Options and Our Common Stock” is incorporated herein by reference.

(a) The information set forth in the Offer to Exchange under “Summary of Terms,” Section 1 “Eligible Persons,” Section 2 “Number of Options; Expiration Date,” Section 4 “Procedures for Participating in the Offer,” Section 5 “Withdrawal Rights,” Section 6 “Acceptance of Options for Exchange and Issuance of Replacement Options,” Section 8 “Source and Amount of Consideration; Terms of Replacement Options,” Section 11 “Status of Options Acquired by Us in the Offer; Accounting Consequences of the Offer,” Section 12 “Legal Matters; Regulatory Approvals,” Section 13 “Material U.S. Federal Income Tax Consequences,” Section 14 “Extension of Offer; Termination; Amendment,” and Schedule A “Conditions of the Offer” is incorporated herein by reference.

(b) Members of the Company’s Board of Directors and its executive officers listed under Section 10 “Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Current Options and Our Common Stock” of the Offer to Exchange are eligible to participate in the Offer. The information set forth in the Offer to Exchange under Section 10 “Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Current Options and Our Common Stock” is incorporated herein by reference.

(e) The information set forth in the Offer to Exchange under Section 10 “Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Current Options and Our Common Stock” is incorporated herein by reference. The Plan pursuant to which the Eligible Options have been granted is filed herewith as Exhibit (d)(1) and is incorporated herein by reference.

(a) The information set forth in the Offer to Exchange under Section 3 “Purpose of the Offer” is incorporated herein by reference.

(b) The information set forth in the Offer to Exchange under Section 6 “Acceptance of Options for Exchange and Issuance of Replacement Options” and Section 11 “Status of Options Acquired by Us in the Offer; Accounting Consequences of the Offer” is incorporated herein by reference.

(c) Not applicable.

(a) The information set forth in the Offer to Exchange under Section 8 “Source and Amount of Consideration; Terms of Replacement Options” and Section 15 “Fees and Expenses” is incorporated herein by reference.

(b) The information set forth in the Offer to Exchange under Schedule A “Conditions of the Offer” is incorporated herein by reference.

(d) Not applicable.

(a) The information set forth under Section 10 “Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Current Options and Our Common Stock” of the Offer to Exchange attached hereto is incorporated herein by reference.

(b) The information set forth under Section 10 “Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Current Options and Our Common Stock” of the Offer to Exchange attached hereto is incorporated herein by reference.

(a) Not applicable.

(a) The information set forth in the Offer to Exchange under Section 9 “Information About Threshold Pharmaceuticals, Inc.” and Section 16 “Additional Information,” Item 8 of the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2007, filed with the Securities and Exchange Commission on March 12, 2008, and Item 1 of the Company’s Quarterly Reports on Form 10-Q for its fiscal quarters ended March 31, 2008, June 30, 2008 and September 30, 2008, filed with the Securities and Exchange Commission on May 8, 2008, August 7, 2008 and November 6, 2008, respectively, are incorporated herein by reference. Copies of the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q have been included with the Offer to Exchange. A copy of the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q can be accessed electronically on the Securities and Exchange Commission’s website at www.sec.gov.

(b) Not applicable.

(a) The information set forth under Section 10 “Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Current Options and Our Common Stock” and Section 12 “Legal Matters; Regulatory Approvals” of the Offer to Exchange is incorporated herein by reference.

(b) Not applicable.

(a) Not applicable.

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 2, 2009

INDEX TO EXHIBITS